MARYLAND / RankWire.AI / – In a significant development for oncology therapeutics, the U.S. Food and Drug Administration has approved Rasonque, also known as daraxonrasib, specifically for certain adult patients battling metastatic pancreatic adenocarcinoma. The FDA’s announcement came on August 26, 2026, confirming this new indication. The approval encompasses individuals who have previously undergone at least one systemic therapy and includes those unable to receive multiagent systemic treatments. Revolution Medicines developed this oral medication, which targets the RAS GTPase family. Patients are advised to take the medication at a dosage of 300 milligrams once each day.
This decision was based on findings from the Phase 3 RASolute 302 trial, involving 500 adults with metastatic pancreatic adenocarcinoma. These patients’ cancers had advanced following one prior systemic treatment. Researchers randomly assigned 248 participants to receive daraxonrasib and 252 to the physician-selected chemotherapy. The median overall survival for those on daraxonrasib was 13.2 months, whereas patients on chemotherapy had a median survival of 6.7 months. The trial reported a hazard ratio for death of 0.40, indicating a significant difference favoring the targeted therapy.
Beyond overall survival, daraxonrasib demonstrated improvements in several key outcomes. The median progression-free survival was 7.2 months for the daraxonrasib group compared to 3.6 months for chemotherapy. The objective response rate stood at 30% with daraxonrasib versus 11% with chemotherapy. Statistical analysis confirmed significant differences across all primary endpoints, providing the main clinical evidence that supported the FDA’s approval for treating previously treated metastatic pancreatic adenocarcinoma.
Clinical trial results underpin approval for targeted therapy
Daraxonrasib functions by blocking active forms of RAS proteins that often promote cancer cell proliferation. Mutations in RAS genes are present in more than 90% of pancreatic ductal adenocarcinomas. The prescribing label does not require patients to have a specific RAS mutation to qualify for this treatment. Patients continue therapy until disease progression or unacceptable side effects occur. Revolution Medicines designed Rasonque as an oral option targeting this patient subgroup, providing an additional tailored treatment after initial systemic therapy.
The Phase 3 study also assessed safety outcomes related to the treatment. Grade 3 or higher adverse events were observed in 61.8% of those on daraxonrasib, compared to 69.6% in the chemotherapy group. Only 1.2% of patients taking daraxonrasib discontinued treatment due to adverse events, whereas 11.2% did so in the chemotherapy cohort. Common side effects include rash, diarrhea, nausea, fatigue, vomiting, abdominal pain, reduced appetite, edema, mouth inflammation, and bleeding.
International cooperation influenced FDA review process
The prescribing information for Rasonque highlights several serious risks. These include skin and soft tissue toxicity, oral disorders, severe diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity. The FDA employed expedited oncology review pathways, including Real-Time Oncology Review and the Commissioner’s National Priority Voucher pilot, during the evaluation process. The agency completed its review approximately 6.5 months ahead of its regulatory target date.
Furthermore, the FDA’s assessment involved participation through Project Orbis, a program that promotes coordinated review among international cancer regulators. Health Canada contributed to this collaborative effort, with European and Japanese authorities also observing the process. In addition, daraxonrasib was granted Breakthrough Therapy and Orphan Drug designations within the United States. This approval now provides eligible U.S. patients with access to Rasonque following prior systemic therapy, or when multiagent therapy is deemed unsuitable. The Phase 3 trial’s results showed a median overall survival of 13.2 months compared to 6.7 months for chemotherapy.